Trastuzumab Deruxtecan (T-DXd) in HER2+ mCRC

April 25, 2024

News

Video

Related Videos

Amma Asare, MD, PhD

Benjamin A. Weinberg, MD

Video 16 - "Neoadjuvant Approach in RAI-R-DTC"

Sundar Jagannath, MBBS

Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"

Elias Jabbour, MD

Rebecca Klisovic, MD

Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein

David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine

Jubilee Brown, MD

Related Content

Anthony M. Hunter, MD

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

Breast Cancer - stock.adobe.com

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

John Ebos, PhD, of Roswell Park Comprehensive Cancer Center

New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy

Gursel Aktan, MD, vice president, global clinical development, Merck Research Laboratories

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

Related Content

Anthony M. Hunter, MD

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

Breast Cancer - stock.adobe.com

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

Andre H. Goy, MD, vice president, physician in chief, Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma, academic chairman, Oncology, Hackensack Meridian School of Medicine; professor, medicine, Georgetown University

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

John Ebos, PhD, of Roswell Park Comprehensive Cancer Center

New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy

Gursel Aktan, MD, vice president, global clinical development, Merck Research Laboratories

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

Latest Conference Coverage

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.